Review ArticleClinical Review

Drug-Induced Hyperpigmentation: Review and Case Series

Rosa M. Giménez García and Sergio Carrasco Molina
The Journal of the American Board of Family Medicine July 2019, 32 (4) 628-638; DOI: https://doi.org/10.3122/jabfm.2019.04.180212

References

  1. 1.↵
    1. Alexis AF,
    2. Sergay AB,
    3. Taylor SC
    . Common dermatologic disorders in skin of color: A comparative practice survey. Cutis 2007;80:387–394.
    OpenUrl
  2. 2.↵
    1. Bastonini E,
    2. Kovacs D,
    3. Picardo M
    . Skin pigmentation and pigmentary disorders: Focus on epidermal/dermal cross-talk. Ann Dermatol 2016;28:279–289.
    OpenUrl
  3. 3.↵
    1. Plensdorf S,
    2. Martinez J
    . Common pigmentation disorders. Am Fam Physician 2009;15;79:109–116.
    OpenUrlPubMed
  4. 4.↵
    1. Dereure O
    . Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001;2:253–262.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Moore DE
    . Drug-induced cutaneous photosensitivity: Incidence, mechanism, prevention and management. Drug Saf 2002;25:345–372.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Kang SJ,
    2. Davis SA,
    3. Feldman SR,
    4. et al
    . Dyschromia in skin of color. J Drugs Dermatol JDD 2014;13:401–406.
    OpenUrl
  7. 7.↵
    1. Al-Khenaizan S,
    2. Al-Berouti B
    . Flagellate pigmentation: A unique adverse effect of bleomycin therapy. Eur J Dermatol EJD 2011;21:146.
    OpenUrl
  8. 8.↵
    1. Murashov MD,
    2. LaLone V,
    3. Rzeczycki PM,
    4. et al
    . The physicochemical basis of clofazimine-induced skin pigmentation. J Invest Dermatol 2018;138:697–703.
    OpenUrl
  9. 9.↵
    1. Eichenfield DZ,
    2. Cohen PR
    . Amitriptyline-induced cutaneous hyperpigmentation: Case report and review of psychotropic drug-associated mucocutaneous hyperpigmentation. Dermatol Online J 2016;17:22(2).
  10. 10.↵
    1. Weiss SR,
    2. Lim HW,
    3. Curtis G
    . Slate-gray pigmentation of sun-exposed skin induced by amiodarone. J Am Acad Dermatol 1984;11(5 Pt 1):898–900.
    OpenUrlPubMed
  11. 11.↵
    1. Krause W
    . Drug-induced hyperpigmentation: A systematic review. J Dtsch Dermatol Ges 2013;11:644–651.
    OpenUrlPubMed
  12. 12.↵
    1. Hu SW,
    2. Robinson MR,
    3. Newlove T,
    4. et al
    . Minocycline-induced hyperpigmentation in multibacillary leprosy. Am J Dermatopathol 2012;34:e114–e118.
    OpenUrlPubMed
  13. 13.↵
    1. Knueppel RC,
    2. Rahimian J
    . Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B. Clin Infect Dis 2007;45:136–138.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Dinkel G,
    2. Kofler L,
    3. Sönnichsen K,
    4. et al
    . Element-specific analysis of a hyperpigmentation caused by levofloxacin therapy. J Dtsch Dermatol Ges 2017;15:949–951.
    OpenUrl
  15. 15.↵
    1. Garval E,
    2. Vuiblet V,
    3. Durlach A,
    4. et al
    . [Skin pigmentation induced by meropenem and levofloxacin]. Ann Dermatol Venereol 2017;144:793–798.
    OpenUrl
  16. 16.↵
    1. Lahiry S,
    2. Choudhury S,
    3. Mukherjee A,
    4. et al
    . Polymyxin B-induced diffuse cutaneous hyperpigmentation. J Clin Diagn Res 2017;11:FD01–FD02.
    OpenUrl
  17. 17.↵
    1. Holdiness MR
    . A review of the Redman syndrome and rifampicin overdosage. Med Toxicol Adverse Drug Exp 1989;4:444–451.
    OpenUrlPubMed
  18. 18.↵
    1. Bilgili SG,
    2. Karadag AS,
    3. Calka O,
    4. et al
    . Isoniazid-induced pellagra. Cutan Ocul Toxicol 2011;30:317–319.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Bahadir S,
    2. Çobanoglu Ü,
    3. Çimsit G,
    4. et al
    . Erythema dyschromicum perstans: Response to dapsone therapy. Int J Dermatol 2004;43:220–222.
    OpenUrlPubMed
  20. 20.↵
    1. Giménez-García R
    . Hyperpigmentation induced by combination therapy with telmisartan-hydrochlorothiazide. J Clin Hypertens 2016;18:361–362.
    OpenUrl
  21. 21.↵
    1. O'Neil MB,
    2. Balfe JW,
    3. Geary DF
    . Drug points: Captopril-related hyperpigmentation. Br Med J Clin Res Ed 1987;295:333.
    OpenUrlFREE Full Text
  22. 22.↵
    1. Scherschun L,
    2. Lee MW,
    3. Lim HW
    . Diltiazem-associated photodistributed hyperpigmentation: A review of 4 cases. Arch Dermatol 2001;137:179–182.
    OpenUrlPubMed
  23. 23.↵
    1. Chawla A,
    2. Goyal S
    . Diltiazem-induced hyperpigmentation in an African American woman. J Am Acad Dermatol 2002;46:468–469.
    OpenUrlPubMed
  24. 24.↵
    1. Erbagci Z
    . Amlodipine associated hyperpigmentation. Saudi Med J 2004;25:103–105.
    OpenUrlPubMed
  25. 25.↵
    1. Kubo Y,
    2. Fukumoto D,
    3. Ishigami T,
    4. et al
    . Diltiazem-associated photodistributed hyperpigmentation: Report of two Japanese cases and published work review. J Dermatol 2010;37:807–811.
    OpenUrlPubMed
  26. 26.↵
    1. Slim R,
    2. Fathallah N,
    3. Larif S,
    4. et al
    . Drug reaction with eosinophilia and systemic symptoms due to lercanidipine. Indian J Dermatol Venereol Leprol 2016;82:324.
    OpenUrl
  27. 27.↵
    1. Bodmer M,
    2. Egger SS,
    3. Hohenstein E,
    4. et al
    . Lichenoid eruption associated with the use of nebivolol. Ann Pharmacother 2006;40:1688–1690.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Aslan AN,
    2. Güney MC,
    3. Akçay M,
    4. et al
    . Lichenoid type cutaneous hyperpigmentation induced by nebivolol. Turk Kardiyol Dern Ars 2017;45:268–270.
    OpenUrl
  29. 29.↵
    1. Lapeere H,
    2. Boone B,
    3. De Schepper S,
    4. et al
    . Hypomelanoses and hypermelanoses. In: Fitzpatrick's dermatology in general medicine. 8th ed. New York, NY: McGraw-Hill; 2012, 804–826.
  30. 30.↵
    1. Buka R,
    2. Hille R,
    3. McCormack P
    . Yellow nail pigmentation following Depakote therapy. J Drugs Dermatol JDD 2003;2:545–547.
    OpenUrl
  31. 31.↵
    1. Gerstner T,
    2. Lipinski C,
    3. Longin E,
    4. et al
    . Valproate-induced change in hair color. J Am Acad Dermatol 2008;58(2 Suppl):S63–S64.
    OpenUrlPubMed
  32. 32.↵
    1. Giménez-García R,
    2. Carrasco-Molina S,
    3. Zambrano-Centeno B
    . Valproic acid-induced hyperpigmentation. J Dermatol 2017;2:16–18.
    OpenUrl
  33. 33.↵
    1. Kanwar AJ,
    2. Jaswal R,
    3. Thami GP,
    4. et al
    . Acquired acromelanosis due to phenytoin. Dermatology 1997;194:373–374.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Muñoz Estrada VF,
    2. Valenzuela Paz GA,
    3. Rochín Tolosa M
    . Estudio de 372 casos de eritema fijo pigmentario. Piel 2011;26:213–220.
    OpenUrl
  35. 35.↵
    1. Kass J,
    2. Hsu S
    . What is your diagnosis? Hyperpigmentation due to long-term chlorpromazine use. Cutis 2001;68:252,–260.
    OpenUrl
  36. 36.↵
    1. Molina-Ruiz AM,
    2. Pulpillo Á,
    3. Molina-Ruiz RM,
    4. et al
    . Chlorpromazine-induced severe skin pigmentation and corneal opacities in a patient with schizophrenia. Int J Dermatol 2016;55:909–912.
    OpenUrl
  37. 37.↵
    1. D'Agostino ML,
    2. Risser J,
    3. Robinson-Bostom L
    . Imipramine-induced hyperpigmentation: A case report and review of the literature. J Cutan Pathol 2009;36:799–803.
    OpenUrlPubMed
  38. 38.↵
    1. Jhirwal OP,
    2. Parsad D,
    3. Basu D
    . Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent. Int J Dermatol 2004;43:778–779.
    OpenUrlPubMed
  39. 39.↵
    1. Singh LK,
    2. Sahu M,
    3. Praharaj SK
    . Olanzapine-induced reversible pellagroid skin lesion. Curr Drug Saf 2015;10:251–253.
    OpenUrl
  40. 40.↵
    1. Cheng YC,
    2. Huang MC
    . Photosensitivity reaction associated with selective serotonin re-uptake inhibitors: Possible cross-sensitivity? Psychiatry Clin Neurosci 2014;68:244.
    OpenUrl
  41. 41.↵
    1. Hendrix JD,
    2. Greer KE
    . Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol 1992;31:458–466.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Linares T,
    2. Marcos C,
    3. Gavilan MJ,
    4. et al
    . Fixed drug eruption due to aceclofenac. Contact Dermatitis 2007;56:291–292.
    OpenUrlPubMed
  43. 43.↵
    1. Sánchez-Morillas L,
    2. Rojas Pérez-Ezquerra P,
    3. González Morales ML,
    4. et al
    . Fixed drug eruption due to ibuprofen with patch test positive on the residual lesion. Allergol Immunopathol (Madr) 2013;41:203–204.
    OpenUrl
  44. 44.↵
    1. Bremec T,
    2. Demsar J,
    3. Luzar B,
    4. et al
    . Longstanding truncal hyperpigmented patches in a young man. Multiple fixed drug eruption caused by acetaminophen. Clin Exp Dermatol 2010;35:e56–e57.
    OpenUrlPubMed
  45. 45.↵
    1. Trujillo MJ,
    2. de Barrio M,
    3. Rodríguez A,
    4. et al
    . Piroxicam-induced photodermatitis. Cross-reactivity among oxicams. A case report. Allergol Immunopathol (Madr). 2001;1;29:133–136.
    OpenUrlPubMed
  46. 46.↵
    1. Reyes-Habito CM,
    2. Roh EK
    . Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: Part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol 2014;71:203.e1–203.e12; quiz 215–216.
    OpenUrl
  47. 47.↵
    1. Youssef M,
    2. Mokni S,
    3. Belhadjali H,
    4. et al
    . Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation. Int J Clin Pharm 2013;35:309–312.
    OpenUrl
  48. 48.↵
    1. Yule SM,
    2. Pearson AD,
    3. Craft AW
    . Ifosfamide-induced hyperpigmentation. Cancer 1994;73:240–241.
    OpenUrlPubMed
  49. 49.↵
    1. Horn TD,
    2. Beveridge RA,
    3. Egorin MJ,
    4. et al
    . Observations and proposed mechanism of N, N′, N″-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation. Arch Dermatol 1989;125:524–527.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Al-Lamki Z,
    2. Pearson P,
    3. Jaffe N
    . Localized cisplatin hyperpigmentation induced by pressure. A case report. Cancer 1996 15;77:1578–1581.
    OpenUrlPubMed
  51. 51.↵
    1. Sanz-Sánchez T,
    2. Córdoba S,
    3. Jiménez-Ayala B,
    4. et al
    . 5-Fluorouracil-induced reticular hyperpigmentation]. Actas Dermosifiliogr 2008;99:573–574.
    OpenUrlPubMed
  52. 52.↵
    1. Vázquez-Bayo C,
    2. Rodríguez-Bujaldón AL,
    3. Jiménez-Puya R,
    4. et al
    . Hiperpigmentación secundaria a capecitabina. Actas Dermo-Sifiliográficas 2007;98:491–493.
    OpenUrl
  53. 53.↵
    1. Teixeira V,
    2. Vieira R,
    3. Figueiredo A
    . Tegafur-induced acral hyperpigmentation. Dermatol Rep. 2011;3;3:e30.
    OpenUrl
  54. 54.↵
    1. Pai GS,
    2. Vimala AM
    . Flagellate pigmentation and sclerodermoid changes: Cutaneous markers of bleomycin toxicity. Indian J Dermatol Venereol Leprol 1999;65:32–35.
    OpenUrlPubMed
  55. 55.↵
    1. Kubba A,
    2. Kubba R,
    3. Batrani M,
    4. et al
    . Argyria an unrecognized cause of cutaneous pigmentation in Indian patients: A case series and review of the literature. Indian J Dermatol Venereol Leprol 2013;79:805–811.
    OpenUrl
  56. 56.↵
    1. Sharma A,
    2. Vora R,
    3. Modi M,
    4. et al
    . Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol 2008;74:234–237.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Capelli L,
    2. Cuello C,
    3. E L,
    4. Garuti RA,
    5. et al
    . Hiperpigmentación cutáneo-mucosa y ungular secundaria a tenofovir. Arch Argent Dermatol 2013;63:23–26.
    OpenUrl
  58. 58.↵
    1. Marcoval J,
    2. Notario J,
    3. Martín C,
    4. et al
    . Pigmentación oral asociada al tratamiento con alfa-interferón y ribavirina para la hepatitis C. Actas Dermo-Sifiliográficas 2014;105:211–212.
    OpenUrl
  59. 59.↵
    1. Balasubramanian P,
    2. Jagadeesan S,
    3. Thomas J
    . Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia. Indian J Dermatol 2015;60:523.
    OpenUrl
  60. 60.↵
    1. Roeker LE,
    2. Wolanskyj AP
    . Imatinib-associated melanosis of the palate. Am J Hematol 2014;89:564.
    OpenUrl
  61. 61.↵
    1. Skare T,
    2. Ribeiro CF,
    3. Souza FHM,
    4. et al
    . Antimalarial cutaneous side effects: A study in 209 users. Cutan Ocul Toxicol 2011;30:45–49.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. de Andrade BAB,
    2. Fonseca FP,
    3. Pires FR,
    4. et al
    . Hard palate hyperpigmentation secondary to chronic chloroquine therapy: Report of five cases. J Cutan Pathol 2013;40:833–838.
    OpenUrl
  63. 63.↵
    1. Jallouli M,
    2. Francès C,
    3. Piette JC,
    4. et al
    . Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: A case-control study. JAMA Dermatol 2013;149:935–940.
    OpenUrl
  64. 64.↵
    1. Rosen T,
    2. Aponte C
    . Cutaneous hyperpigmentation due to chronic quinine ingestion. Cutis 2005;75:114–116.
    OpenUrl
  65. 65.↵
    1. Takita Y,
    2. Ichimiya M,
    3. Hamamoto Y,
    4. Muto M
    . A case of carotenemia associated with ingestion of nutrient supplements. J Dermatol 2006;33:132–134.
    OpenUrlPubMed
  66. 66.↵
    1. Thomas P,
    2. Dalle E,
    3. Revillon B,
    4. et al
    . [Cutaneous effects in hormonal contraception]. NPN Med 1985;5:19–24.
    OpenUrlPubMed
  67. 67.↵
    1. Ammoury A,
    2. Michaud S,
    3. Paul C,
    4. et al
    . Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: Molecular characterization of amiodarone in the skin. Arch Dermatol 2008;144:92–96.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Stähli BE,
    2. Schwab S
    . Amiodarone-induced skin hyperpigmentation. QJM Mon J Assoc Physicians 2011;104:723–724.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Flowers H,
    2. Brodell R,
    3. Brents M,
    4. Wyatt JP
    . Fixed drug eruptions: presentation, diagnosis, and management. South Med J 2014;107:724–727.
    OpenUrl
  70. 70.↵
    1. Vachiramon V,
    2. McMichael AJ
    . Approaches to the evaluation of lip hyperpigmentation. Int J Dermatol 2012;51:761–770.
    OpenUrlPubMed
  71. 71.↵
    1. Filitis DC,
    2. Graber EM
    . Minocycline-induced hyperpigmentation involving the oral mucosa after short-term minocycline use. Cutis 2013;92:46–48.
    OpenUrl
  72. 72.↵
    1. Ricci F,
    2. De Simone C,
    3. Regno L,
    4. et al
    . Drug-induced hair colour changes. Eur J Dermatol 2016;26:531–536.
    OpenUrl
  73. 73.↵
    1. Piraccini BM,
    2. Alessandrini A
    . Drug-related nail disease. Clin Dermatol 2013;31:618–626.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords